{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037131","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2026-08-11T20:10:35+00:00","discovered_at":"2026-08-11T20:12:00.387415+00:00","generated_at":"2026-08-11T20:12:44.737692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sanara Q2 revenue up 9% to $28.1M; adjusted EBITDA $5.0M; MIMEDX acquisition pending","bullets":["Q2 net revenue $28.1M (+9% YoY); gross margin 93%; adjusted EBITDA $5.0M vs $4.7M.","Net loss from continuing ops $0.4M ($0.05/diluted share) vs net income $0.5M ($0.05/share) in Q2 2025.","H1 2026 revenue $55.9M (+14% YoY); adjusted EBITDA $9.3M vs $7.4M.","Cash and equivalents $15.4M; long-term debt $46.5M at June 30, 2026 vs $16.6M and $46.0M at Dec 31, 2025.","Announced transformational acquisition by MIMEDX, expected to combine surgical portfolios; subject to customary closing conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037131","json":"https://secwatch.observer/filing/0001493152-26-037131.json","markdown":"https://secwatch.observer/filing/0001493152-26-037131.md","text":"https://secwatch.observer/filing/0001493152-26-037131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/0001493152-26-037131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315226037131/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:12:44.737692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}